Pancreatic cancer is widely regarded as the hardest cancer to detect, with 80 to 85% of patients already having locally advanced or metastatic disease by the time they receive a diagnosis. But it’s not the only cancer that routinely evades early detection. Ovarian cancer, lung cancer, liver cancer, and esophageal cancer all share traits that make them difficult to catch before they spread: they grow in hard-to-reach locations, produce vague symptoms, and lack reliable screening tests for the general population.
Why Pancreatic Cancer Tops the List
The pancreas sits deep in the abdomen, tucked behind the stomach and surrounded by other organs. Tumors growing there can’t be felt during a physical exam, and they don’t press on structures that would cause obvious symptoms until they’re large enough to invade surrounding tissue. Only 15 to 20% of patients have tumors that are still surgically removable at diagnosis.
The symptoms that do eventually appear, such as abdominal discomfort, back pain, weight loss, nausea, and new-onset diabetes, overlap with dozens of common, less serious conditions. Jaundice (yellowing of the skin and eyes) is one of the more distinctive signs, but it typically signals that the tumor has already grown large enough to block the bile duct. There is no recommended routine screening test for pancreatic cancer in people at average risk, which means most cases are found only after symptoms become impossible to ignore.
The survival gap between early and late detection is enormous across all of these cancers, but pancreatic cancer illustrates it starkly. When caught at a localized stage, the five-year survival rate for pancreatic cancer is roughly 44%. Once it has spread to distant organs, that number drops to around 3%.
Ovarian Cancer and the Screening Problem
Ovarian cancer is sometimes called a “silent” cancer because its early symptoms, including bloating, pelvic pressure, feeling full quickly, and changes in bathroom habits, are things most women experience from time to time without alarm. By the time these symptoms become persistent enough to prompt investigation, the cancer has often spread beyond the ovaries.
What makes ovarian cancer especially frustrating is that screening tools exist but don’t work well enough to recommend for the general population. The blood marker CA-125, which rises with ovarian cancer, is elevated above the standard cutoff in about 5% of healthy women. In one study, 80% of women with elevated CA-125 levels did not have ovarian cancer. The positive predictive value of a single CA-125 test in average-risk women is around 1%, meaning that for every 100 positive results, only one woman actually has cancer. The other 99 face unnecessary anxiety, follow-up procedures, and sometimes surgery. About 15% of healthy women who underwent surgery after a false positive experienced surgical complications.
Combining CA-125 with transvaginal ultrasound improves accuracy somewhat, reaching about 86% sensitivity with 99.8% specificity in one large trial. But even that combination hasn’t been shown to reduce ovarian cancer deaths in the general population, which is why major medical organizations don’t recommend routine screening for women at average risk.
Lung Cancer’s Detection Gap
Lung cancer does have an effective screening tool: low-dose CT scans. But it’s only recommended for a narrow group of people. Current guidelines limit screening to adults aged 50 to 80 who have smoked at least 20 pack-years (the equivalent of one pack a day for 20 years) and who either still smoke or quit within the past 15 years. Everyone else, including the roughly 10 to 20% of lung cancer patients who have never smoked, falls outside these criteria.
The lungs have no pain-sensing nerves in most of their tissue, so a tumor can grow for months or years without causing discomfort. Early symptoms like a lingering cough, mild shortness of breath, or fatigue are easy to dismiss or attribute to a cold, allergies, or aging. By the time symptoms like coughing up blood or significant weight loss appear, the disease is often advanced. The five-year survival rate for localized non-small cell lung cancer is 67%, but for distant-stage disease it falls to just 9%. For small cell lung cancer, those numbers are 34% localized and 4% distant.
Esophageal and Liver Cancer
Esophageal cancer develops inside a tube that can stretch to accommodate a growing tumor before causing noticeable trouble. The hallmark symptom, difficulty swallowing, usually doesn’t appear until the tumor has narrowed the esophagus significantly. While endoscopy is considered the gold standard for detecting esophageal cancer, routine endoscopy isn’t recommended for the general population. Screening is reserved for people with specific risk factors like long-standing acid reflux disease or Barrett’s esophagus, leaving many cases undetected until late stages.
Liver cancer follows a similar pattern. It most commonly develops in people with chronic liver disease or cirrhosis, and those patients are typically offered ultrasound surveillance every six months. But for people who don’t know they have underlying liver damage, or whose liver disease hasn’t been diagnosed, liver cancer can grow silently. The liver is a large organ with significant functional reserve, meaning it can continue working relatively normally even when a tumor is present. Symptoms like unexplained weight loss, loss of appetite, or upper abdominal pain tend to surface late.
What These Cancers Have in Common
The cancers that are hardest to detect share a few key characteristics. First, they grow in organs located deep inside the body where tumors aren’t visible or easily felt. Second, their early symptoms are either nonexistent or so generic (fatigue, bloating, mild pain, digestive changes) that they mimic everyday complaints. Third, and perhaps most critically, there is no proven, cost-effective screening test recommended for average-risk people. Breast cancer has mammograms, cervical cancer has Pap smears, and colorectal cancer has colonoscopies. Pancreatic, ovarian, and many other cancers have nothing equivalent.
Subtle Signs Worth Paying Attention To
Because routine screening isn’t available for many of these cancers, awareness of persistent or unusual changes in your body becomes especially important. Some signals that warrant a conversation with a doctor include:
- Unexplained bleeding: blood in your stool (which can look dark or tarry), blood in urine, coughing up blood, abnormal vaginal bleeding, or bloody nipple discharge.
- Difficulty swallowing: feeling like food gets stuck in your throat, or progressive trouble getting solid foods down.
- Persistent fullness or appetite changes: feeling full after eating very little, or losing your appetite for weeks without explanation.
- New shortness of breath: getting winded during activities that previously felt easy, like climbing stairs or walking at a normal pace.
- Changes in bowel or bladder habits: new constipation or diarrhea that persists, difficulty passing urine or stool, or the sensation that your bowels aren’t emptying completely.
None of these symptoms means you have cancer. Most of the time, there’s a less serious explanation. But when they persist for more than a few weeks, or when multiple vague symptoms appear together, they deserve medical evaluation rather than dismissal.
Blood Tests That Screen for Multiple Cancers
A new category of blood tests called multi-cancer early detection (MCED) tests is designed specifically to find cancers that lack standard screening, including pancreatic and ovarian cancers. These tests analyze fragments of DNA shed by tumors into the bloodstream and use machine learning to identify cancer signals and predict where in the body the cancer is located.
The most established of these, Galleri by GRAIL, is already commercially available. In clinical studies, it detected cancer signals with 99.5% specificity and an overall sensitivity of 51.5%. For stage I through III cancers, sensitivity was about 41%, meaning it catches roughly two in five early-to-mid-stage cancers. Notably, 71% of the cancers it detected were types without standard screening tests, and half of those were found at stage I or II. The NHS in the UK is running a large trial and expects final results by 2026 before deciding on broader use.
Another test, CancerSEEK (now called Cancerguard), has received breakthrough device designation from the FDA. It showed particularly high sensitivity for ovarian cancer (98%), liver cancer (95%), and stomach cancer (90%) in initial studies, though its sensitivity for stage I cancers across all types was only about 40%. A Chinese study of over 123,000 participants using a test called PanSeer identified 95% of patients from blood samples taken before they had any cancer symptoms.
These tests are not yet a replacement for established screening programs, and a negative result doesn’t guarantee you’re cancer-free. But they represent the most promising shift in decades for cancers that have historically been diagnosed far too late.